Aneurysm-related mortality rates in the US AneuRx clinical trial
| Autor: | Lazar J. Greenfield, Thomas P. Gross, Chih Hsin Liu, Dale R. Tavris |
|---|---|
| Rok vydání: | 2010 |
| Předmět: |
medicine.medical_specialty
Endoleak medicine.medical_treatment Aortic Rupture Risk Assessment Cohort Studies Blood Vessel Prosthesis Implantation Aneurysm Absorbable Implants medicine Humans Surgical Wound Infection Device Removal business.industry Mortality rate Medical record Stent medicine.disease Abdominal aortic aneurysm United States Surgery Blood Vessel Prosthesis Clinical trial Causality Survival Rate Cohort Quality of Life Stents Implant business Aortic Aneurysm Abdominal Follow-Up Studies |
| Zdroj: | Journal of the American College of Surgeons. 211(5) |
| ISSN: | 1879-1190 |
| Popis: | Background The AneuRx (Medtronic) stent graft was approved by the FDA in September 1999. The purpose of this study was to ascertain the aneurysm-related mortality rate of a subgroup of the patient cohort from Medtronic's investigational premarket study. Study Design There were 931 study subjects, from 19 medical centers, who were followed for an average of 3.48 years. Abdominal aortic aneurysm (AAA)-related mortality rates were examined, using death certificates and medical records. Results The 1-month postimplant death rate was 1.61%. Not counting deaths related to the initial implant, there was an increase in the rate of AAA-related mortality after 3 years, from an average of 0.18% in the first 3 years to an average of 1.39% in years 4 and 5. Conclusions Mortality in patients implanted with an AneuRx graft (as determined in this study) probably exceeds that of open procedure patients (based on medical literature) at some point in time, likely within 4 years after implant. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|